IGM 2537
Alternative Names: IGM-2537Latest Information Update: 31 Jan 2024
At a glance
- Originator IGM Biosciences
 - Class Antineoplastics; Bispecific antibodies; Immunotherapies
 - Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Suspended Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
 
Most Recent Events
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
 - 07 Dec 2023 Suspended - Preclinical for Acute myeloid leukaemia in USA (Parenteral)
 - 07 Dec 2023 Suspended - Preclinical for Myelodysplastic syndromes in USA (Parenteral)